These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9173574)

  • 1. [Initial experience in the diagnosis of thrombophilia due to activated protein C resistance].
    Barkagan ZS; Gervaziev VB; Tsyvkina LP; Mamaev AN; Karpenko AA; Tseĭmak IIa
    Ter Arkh; 1997; 69(2):35-7. PubMed ID: 9173574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I
    Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to activated protein C: a major cause of inherited thrombophilia.
    Jensen R; Ens GE
    Clin Lab Sci; 1997; 10(4):219-22. PubMed ID: 10169621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
    Toulon P
    Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostasis during normal pregnancy and puerperium.
    Hellgren M
    Semin Thromb Hemost; 2003 Apr; 29(2):125-30. PubMed ID: 12709915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activated protein C resistance--a recently discovered hereditary thrombophilia].
    Moland L; Sandset PM
    Tidsskr Nor Laegeforen; 1998 Sep; 118(23):3590-5. PubMed ID: 9820002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antithrombotic effect of protein C activator from a snake venom].
    Strukova SM; Kogan AE; Tara AA; Aaviksaar AA
    Vopr Med Khim; 1989; 35(5):115-9. PubMed ID: 2617927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
    Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
    Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Activated protein C resistance in Behçet disease].
    Guermazi S; M'Rad S; Lamloum M; Houman MH; Hamza M; Ben Dridi M; Miled M; Dellagi K
    Pathol Biol (Paris); 1998 Dec; 46(10):791-5. PubMed ID: 9922996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
    Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
    Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical diagnosis of thrombosis and blood coagulation tests].
    Watanabe K
    Rinsho Byori; 1998 Mar; 46(3):235-44. PubMed ID: 9564763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B
    J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired activated protein C-resistance in patients with lupus anticoagulants.
    Ehrenforth S; Radtke KP; Scharrer I
    Thromb Haemost; 1995 Aug; 74(2):797-8. PubMed ID: 8585027
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.